Vaxart, Inc. (NASDAQ:VXRT) Short Interest Up 17.0% in February

Vaxart, Inc. (NASDAQ:VXRT) was the target of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 13,280,000 shares, an increase of 17.0% from the February 13th total of 11,350,000 shares. Currently, 6.0% of the company’s shares are sold short. Based on an average daily volume of 1,960,000 shares, the days-to-cover ratio is presently 6.8 days.

Vaxart Trading Up 2.4 %

Shares of NASDAQ:VXRT opened at $0.58 on Thursday. The company has a market capitalization of $132.85 million, a price-to-earnings ratio of -1.42 and a beta of 1.69. Vaxart has a 12-month low of $0.45 and a 12-month high of $1.41. The business has a 50-day moving average price of $0.66 and a 200 day moving average price of $0.71.

Institutional Investors Weigh In On Vaxart

A number of institutional investors have recently made changes to their positions in VXRT. XTX Topco Ltd boosted its position in shares of Vaxart by 869.3% during the 3rd quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock worth $116,000 after purchasing an additional 122,387 shares during the period. Geode Capital Management LLC lifted its stake in Vaxart by 15.8% during the third quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company’s stock worth $2,160,000 after purchasing an additional 346,725 shares in the last quarter. Squarepoint Ops LLC lifted its stake in Vaxart by 95.0% during the fourth quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 251,789 shares in the last quarter. Graham Capital Management L.P. boosted its position in shares of Vaxart by 155.8% during the fourth quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company’s stock worth $35,000 after buying an additional 32,482 shares during the period. Finally, Bank of America Corp DE grew its stake in shares of Vaxart by 10.8% in the fourth quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 17,942 shares in the last quarter. 18.05% of the stock is currently owned by institutional investors and hedge funds.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.